1. Home
  2. NMM vs COLL Comparison

NMM vs COLL Comparison

Compare NMM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$52.18

Market Cap

1.3B

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$49.69

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMM
COLL
Founded
2007
2002
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
NMM
COLL
Price
$52.18
$49.69
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$47.50
AVG Volume (30 Days)
104.1K
488.1K
Earning Date
02-12-2026
11-06-2025
Dividend Yield
0.38%
N/A
EPS Growth
N/A
N/A
EPS
8.91
1.63
Revenue
$1,311,114,000.00
$757,067,000.00
Revenue This Year
N/A
$26.35
Revenue Next Year
$15.22
$3.67
P/E Ratio
$5.85
$30.66
Revenue Growth
N/A
26.34
52 Week Low
$28.37
$23.23
52 Week High
$56.44
$50.01

Technical Indicators

Market Signals
Indicator
NMM
COLL
Relative Strength Index (RSI) 54.07 68.36
Support Level $51.01 $48.50
Resistance Level $51.75 $49.92
Average True Range (ATR) 1.09 1.26
MACD -0.12 -0.22
Stochastic Oscillator 49.50 74.19

Price Performance

Historical Comparison
NMM
COLL

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: